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Abstract
Radiotherapy is a widely used treatment option in cancer. However, recent evidence suggests that doses of ionizing
radiation (IR) delivered inside the tumor target volume, during fractionated radiotherapy, can promote tumor invasion and
metastasis. Furthermore, the tissues that surround the tumor area are also exposed to low doses of IR that are lower than
those delivered inside the tumor mass, because external radiotherapy is delivered to the tumor through multiple radiation
beams, in order to prevent damage of organs at risk. The biological effects of these low doses of IR on the healthy tissue
surrounding the tumor area, and in particular on the vasculature remain largely to be determined. We found that doses of IR
lower or equal to 0.8 Gy enhance endothelial cell migration without impinging on cell proliferation or survival. Moreover,
we show that low-dose IR induces a rapid phosphorylation of several endothelial cell proteins, including the Vascular
Endothelial Growth Factor (VEGF) Receptor-2 and induces VEGF production in hypoxia mimicking conditions. By activating
the VEGF Receptor-2, low-dose IR enhances endothelial cell migration and prevents endothelial cell death promoted by an
anti-angiogenic drug, bevacizumab. In addition, we observed that low-dose IR accelerates embryonic angiogenic sprouting
during zebrafish development and promotes adult angiogenesis during zebrafish fin regeneration and in the murine
Matrigel assay. Using murine experimental models of leukemia and orthotopic breast cancer, we show that low-dose IR
promotes tumor growth and metastasis and that these effects were prevented by the administration of a VEGF receptor-
tyrosine kinase inhibitor immediately before IR exposure. These findings demonstrate a new mechanism to the
understanding of the potential pro-metastatic effect of IR and may provide a new rationale basis to the improvement of
current radiotherapy protocols.
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Introduction
Radiotherapy is a widely used local treatment for malignant
tumors, characterized by uncontrolled growth and the ability of
invading adjacent tissues and metastasize. While radiotherapy has
been classically viewed to exert its therapeutic effect by killing
tumor cells, emerging evidence indicates that effects extend
beyond cancer cell death. Ionizing radiation (IR) changes the
microenvironment, contributing to anti-tumor effects of radio-
therapy [1]. However, there are clinical and experimental
observations indicating that IR might promote a metastatic
behavior of cancer cells and that the irradiated host microenvi-
ronment might exert tumor-promoting effects [1,2]. Therefore, a
careful analysis of the putative tumor-promoting and pro-
metastatic effect of IR is imperative, as radiotherapy is an essential
part of cancer treatment. Several tumor-associated host cells
including endothelial cells, leukocytes, macrophages, fibroblasts,
myofibroblasts and nerve cells populate the tumor microenviron-
ment. Recently, different studies have focused on the mechanisms
by which IR activates cellular targets potentially contributing to
invasion and metastasis [3,4,5,6]. Doses of IR causing such
stimulating effects are classically delivered inside the tumor target
volume in daily small fractions in order to limit damage of healthy
tissues and until a potentially curative dose has accumulated inside
the tumor volume. Furthermore, the delivery in small fractions
and the isodose distributions of external beam radiotherapy result
in lower doses of IR outside the tumor target volume. The
biological effects of these low doses of IR on the healthy tissue
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remain largely to be determined.
Here we report that, in vitro, IR doses lower than 0.8 Gy do not
cause cell cycle arrest or apoptosis. We found that low-dose IR led
to the phosphorylation of several cellular proteins including VEGF
receptor-2 (VEGFR-2). By activating VEGFR-2, low-dose IR
enhances endothelial cell migration and prevents endothelial cell
death promoted by the VEGF-neutralizing antibody bevacizu-
mab. Also, under hypoxic conditions low-dose IR upregulates
VEGF. We further show that, in zebrafish, low-dose IR accelerates
sprouting angiogenesis during development and enhances the
angiogenic response during caudal fin regeneration. Using
different mouse models, we show that low-dose IR promotes
angiogenesis resulting in accelerated tumor growth and metastasis
formation in a VEGFR-dependent manner.
These observations provide novel insights into the mechanisms
involved in the pro-metastatic effect of IR and open novel
therapeutic perspectives for the improvement of current radio-
therapy protocols.
Results
Low-dose IR promotes endothelial cell migration without
causing cell cycle arrest or apoptosis
To investigate the biological effects of low doses of IR on
endothelial cells, we exposed lung human microvascular endothe-
lial cells (HMVEC-L) to doses lower than 2.0 Gy and assess effects
on cell proliferation, survival and migration. We found that 0.5
and 0.8 Gy did not modulate HMVEC-L proliferation, while
doses higher than 1.0 Gy caused a significant decrease of their
proliferation rate (Figure 1A). Accordingly, detailed analysis of cell
cycle profile did not reveal any significant changes in phase
distribution in cells irradiated with 0.5 or 0.8 Gy (Figure 1B). The
impact of low-dose IR on HMVEC-L survival was also evaluated.
No effect on cell viability was detected at doses up to 1.0 Gy,
whereas higher doses (i.e. 10.0 and 20.0 Gy) caused increased cell
death (Figure 1C). Moreover, we assessed the migration of
HMVEC-L exposed to low-dose IR by the scratch wound healing
assay. Doses of 0.5 and 0.8 Gy stimulated HMVEC-L migration
and wound closure, whereas cells irradiated with 1.0 Gy presented
a migration rate similar to non-irradiated controls (Figure 1D). To
examine whether low-dose IR nevertheless induced DNA double-
strand breaks we monitored H2AX phosphorylation [7]. As early
as 30 min after irradiation the c-H2AX foci were detected in a
dose dependent manner in the nuclei of irradiated cells (Figure
S1). At 12 h post-irradiation, c-H2AX was no longer detectable in
cells irradiated at low doses reflecting effective DNA double-strand
break repair.
Taken together these results indicate that doses of 0.5 or 0.8 Gy
promote endothelial cell migration and, in spite of induction of
DNA double-strand breaks they do not impinge on endothelial cell
proliferation or survival.
Low-dose IR activates the PI3K/Akt and MEK/ERK
signaling pathways and prevents apoptosis induced by
PI3K or MEK inhibition
Next, we investigated whether low-dose IR could activate
intracellular signaling pathways associated with cell survival and
migration. To this end, HMVEC-L were exposed to 0.5 Gy and
global protein phosphorylation was analysed. A transient
increase in tyrosine phosphorylation of multiple proteins was
evident 5 min post-irradiation, but no longer detected after
10 min (Figure 2A and 2B), suggesting the rapid triggering of
tyrosine kinase activity upon irradiation. Next, we evaluated the
activation of PI3K/Akt and MEK/ERK signaling pathways. We
observed a slight but significant increase in phosphorylation of
Akt and ERK upon exposure to 0.1, 0.3 or 0.5 Gy (Figure 2C).
To assess the functional relevance of IR-induced activation of
Akt and ERK, HMVEC-L cultured in the presence of specific
inhibitors of PI3K (Ly294002) or MEK (U0126) were exposed or
not to 0.1, 0.3 or 0.5 Gy. Treatment with either of these
inhibitors decreased HMVEC-L viability, although to different
extents. Remarkably, low-dose IR treatment significantly pro-
tected HMVEC-L from death induced by the signaling inhibitors
(Figure 2 D).
Low-dose IR promotes endothelial cell migration and
protects microvasculature from bevacizumab-induced
cell death by activating VEGFR-2
The previous results incited us to test the effect of low-dose IR
on HMVEC-L death induced by the inhibition of VEGF, a main
survival factor for endothelial cells and a target for anti-angiogenic
therapies. HMVEC-L were incubated with bevacizumab (Avas-
tinH), a monoclonal antibody that inhibits the biologic activity of
VEGF, before exposure to low-dose IR. Bevacizumab treatment
reduced HMVEC-L viability and low-dose IR significantly
protected against bevacizumab-induced death (Figure 3A). The
same low-dose IR did not protect against cell death induced by
different chemotherapeutic agents (Figure S2). Based on its ability
of low-dose IR to induce protein phosphorylation, we hypothe-
sized that low-dose IR counteracted the pro-apoptotic effect of
bevacizumab by activating VEGF receptor-2 (VEGFR-2). Con-
sistent with this hypothesis, we found a significant increase in
VEGFR-2 phosphorylation in response to 0.1 Gy (Figure 3B). To
test the functional impact of VEGFR-2 activation, HMVEC-L
were cultured in the presence of bevacizumab and treated or not
with a VEGFR-2 tyrosine kinase inhibitor (TKI) prior to 0.1 Gy of
IR. We found that the protective effect was completely abrogated
by treatment with VEGFR-2 TKI (Figure 3C). Molecularly, we
demonstrated that the VEGFR-2 TKI, in contrast to bevacizu-
mab, inhibited VEGFR-2 phosphorylation induced by 0.1 Gy.
(Figure 3D). Since VEGFR-2 activation has been reported to
promote endothelial cell migration [8], we investigated whether
low-dose IR promotes endothelial cell migration (Figure 1D)
through the activation of VEGFR-2. HMVEC-L were treated or
not with VEGFR-2 TKI prior to 0.5 Gy of IR and cell migration
was assessed by the scratch wound healing assay. We found that
the pro-migratory effect promoted by low dose IR was significantly
abrogated by treatment with VEGFR-2 TKI (Figure S3).
Taken together these results demonstrate that low-dose IR
enhances endothelial migration and prevents endothelial cell death
promoted by the VEGF-neutralizing antibody bevacizumab, by
inducing VEGFR-2 phosphorylation.
Low-dose IR induces VEGF expression in endothelial cells
under conditions mimicking hypoxia
We next asked the question whether low-dose IR modulates the
expression of VEGF in endothelial cells. Under normoxic
conditions, endothelial cells constitutively express very low levels
of VEGF [9]. Low-dose IR did not induce VEGF expression
under normoxic conditions (data not shown). However, in
HMVEC-L cultures first exposed to cobalt chloride (CoCl2),
which mimics hypoxic conditions, and subsequently treated with
0.3 Gy of IR, we observed a greater increase of VEGF mRNA
levels compared to cells treated with CoCl2 alone (Figure 4A).
Consistent with increase VEGF mRNA expression, we also
observed increased levels of secreted VEGF protein (Figure 4B).
Low-Dose IR Is Pro-Angiogenic
PLoS ONE | www.plosone.org 2 June 2010 | Volume 5 | Issue 6 | e11222Figure1. Low-dose IR promotes endothelialcell migration without causing cell cycle arrest orapoptosis. (A) HMVEC-Lwere plated at equal
densities and, after 12 h, left untreated or exposed to 0.5, 0.8, 1.0, 1.5 and 2.0 Gy. After 72 h, the cells were counted using a Nucleocounter. The values
(means 6 s.d.) represent the ratio between cell number of irradiated and non-irradiated conditions and are derived from four independent experiments.
* P,0.02. (B) HMVEC-L were exposed or not to 0.5, 0.8 and 2.0 Gy. Cell cycle profiles were assessed by flow cytometric analysis after 72 h of culture. Data
are representative ofthreeindependent experiments. (C) Thepercentage ofapoptotic cells was determinedbyflowcytometryatthe indicatedtime. Cells
cultured without serum (Dep) were used as cell death control. Values are given as the percentage of viable cells (Annexin V, PI negative) remaining in
culture. Data are shown as mean in triplicate culture and are representative of three independent experiments. (D) Confluent monolayers of HMVEC-L
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in endothelial cells under hypoxia-mimicking conditions.
Low-dose IR accelerates angiogenic sprouting during
zebrafish embryonic development and enhances
angiogenesis during zebrafish fin regeneration
To ascertain whether low-dose IR was able to enhance
angiogenesis in vivo, we used the transgenic zebrafish fli1:EGFP,
which allow intra vital imaging of the vasculature through fli1 gene
promoter-driven expression of GFP in endothelial cells. The first
blood vessels formed in zebrafish embryo arise through vasculo-
genesis. The smaller vessels are then formed through angiogenic
sprouting from these large vessels [10]. Fli1:EGFP zebrafish
embryos were exposed to 0.5 Gy IR 3 days post-fertilization (dpf),
a time of angiogenic sprouting, and the formed vasculature was
examined 7 dpf. All non-irradiated embryos (n=70) showed
vertical, parallel-oriented and regularly spaced Sub-Intestinal
Vessels (SIV), while 52 out of 70 irradiated embryos (74%),
showed more and irregularly-shaped vessels between larger SIV
(Figure 5A). We also found that these numerous vessels were
formed by sprouting angiogenesis (Figure 5B). At a later time point
(17 dpf), SIV vascular pattern was identical in non-irradiated
embryos (Figure 5C), indicating that low-dose IR accelerated
angiogenic sprouting without causing excessive vessel formation.
To test whether low-dose IR also stimulated angiogenesis in adult
animals, adult fli1:EGFP zebrafish were subjected to caudal fin
amputation at mid-fin level,exposed ornot to 0.5 Gy ofIR and then
allowed to recover. Zebrafish caudal fin growth is accompanied by
active angiogenesis [11]. Results showed a striking increase in the
inter-ray vessel density in the irradiated regenerating fin (Figure 5D).
Taken together, these data demonstrate that low-dose IR
accelerates sprouting angiogenesis from SIV during zebrafish
embryonic development, and enhances the angiogenic response
during fin regeneration.
Low-dose IR promotes angiogenesis in the murine
Matrigel plug assay
To test whether low-dose IR also stimulates angiogenesis in
mammals, we used the murine Matrigel plug angiogenesis assay
[12]. Athymic Swiss nu/nu mice were locally irradiated (lower-right
back side) with 0.3 Gy, and growth-factor-depleted Matrigel plugs
supplemented with fibroblast growth factor 2 (FGF2) were
implanted 24 h later, within irradiated or non-irradiated tissue
(the contralateral non-irradiated side was used as matched
controls). Matrigel plugs were analyzed 5 days later, a time point
where angiogenesis is naturally heterogeneous and not fully
formed, thereby facilitating the detection of stimulatory effects,
while at later times (7 to 10 d) angiogenesis is more homogenous
and robust, which may mask stimulatory effects. Consistently, the
degree of angiogenesis ranged from high to low across different
plugs. Tissue pre-irradiation enhanced angiogenesis, albeit to
different extents in the individual mice (Figure 6A and 6B).
These data demonstrate that low-dose IR significantly promotes
angiogenesis in adult mice.
Low-dose IR promotes acceleration of tumor growth and
metastasis in a VEGF receptor-dependent manner
We asked whether low-dose IR had an impact in promoting
tumor growth and dissemination. Six weeks-old NOD-SCID mice
were irradiated or not with 0.3 Gy and subsequently injected
intravenously with MOLT-4 cells. After 14 d, irradiated mice
showed a significant increase in MOLT-4 tumor burden when
compared to non-irradiated animals (Figure 7A).
Next, we investigated whether VEGFR activation could be
involved in the acceleration of tumor growth promoted by low-
dose IR. To this purpose, we administered the VEGF receptor
tyrosine kinase inhibitor, PTK/ZK, 2h before irradiation with
0.3 Gy, and MOLT-4 cells were injected 24 h later. At this time
point PTK/ZK is no longer active in vivo, thereby excluding
possible direct effects on leukemia cells. After 14 d, leukemia
burden in irradiated mice treated with PTK/ZK was significantly
lower than in irradiated animals treated with vehicle only, and was
similar to the tumor burden observed in non-irradiated mice
(Figure 7B).
We also investigated whether low-dose IR could also promote
tumor metastasis by using the 4T1 orthotopic implantation mouse
model of spontaneous breast cancer metastasis to the lung [13].
NOD-SCID IL-2Rgamma
null mice were treated or not with
PTK/ZK and 2 h later exposed or not to 0.3 Gy, whole body IR.
After 22 h, 5610
4 4T1 cells were injected into the 4
th mammary
fatpad of the mice in all four groups. Non-irradiated mice treated
with PTK/ZK were also used as a control, to ensure that the
single PTK/ZK treatment administered 24 h before 4T1 cell
injection would not affect tumor growth. Twenty days post-
transplantation, no difference in primary tumor growth between
the groups of mice was found (data not shown). Primary tumors
were surgically removed and a significantly higher bioluminescent
signal was detected in the chest region of the irradiated group
when compared to other groups, where the signal was similar
(Figure 7C). By Computed Tomography (CT) scan, we found
more nodules in both lobes of irradiated lungs, when compared to
other groups (Figure 7D). To confirm the bioluminescent and CT
results, lungs were analysed by histology at necropsy. Accordingly,
number of metastasized 4T1 cells in the lungs of experimental
mice groups was similar, except in the irradiated one, in which we
observed an increased number and size of lung metastases
(Figure 7E).
Taken together, these results indicate that low-dose IR
promotes acceleration of tumor growth and enhances the
metastatic spreading in a VEGFR-dependent manner.
Discussion
There is growing evidence in the literature indicating that IR
may have pro-metastatic effects [2]. It is generally assumed that
tumor progression towards metastasis, during or after therapy, is
due to the appearance of resistant tumor cells. However, several
studies indicate that radiotherapy also rapidly and persistently
alters the tumor microenvironment. IR induces the production of
pro-angiogenic molecules [4], which may activate the microenvi-
ronment, including the vasculature. In accordance, anti-angio-
genic approaches enhance anti-tumor effects of IR [14,15,16,17].
On the other hand, while adjuvant radiotherapy significantly
improves local tumor control, recurrences within a preirradiated
field are associated with higher risk of local invasion and metastasis
and with poor prognosis [18,19,20].
Furthermore, the tissues that surround the tumor area are also
exposed to low doses of IR that are lower than those delivered
inside the tumor mass, because external radiotherapy is delivered
were subjected to in vitro wound healing and exposed or not to 0.5, 0.8 or 1.0 Gy. Photographs were taken immediately (not shown) and 9 h after
wounding. Quantification of the wound area (in mm
2) is presented below the images. Data are representative of five independent experiments.
doi:10.1371/journal.pone.0011222.g001
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PLoS ONE | www.plosone.org 4 June 2010 | Volume 5 | Issue 6 | e11222Figure2.Low-doseIRactivatesPI3K/AktandMEK/ERKpathwaysandpreventsapoptosisinducedbytheirinhibition.(AandB)HMVEC-L
were exposed or not to 0.5 Gy and incubated for the time indicated. (A) Representative blots from three independent experiments. Top, Tyrosine
phosphorylation Western blot; Bottom, b-tubulinWestern blot to verify equal sample loading. (B) Tyrosine phosphorylationlevelswere assessed by flow
cytometry. The values (means 6 s.d.) represent the ratio between median fluorescence intensity of irradiated cells and non-irradiated cells and are
derived from four independent experiments. (C)Representative blots from three independent experiments. Western blot analysis of total-, phospho-Akt
(P-AKT) (left) and total-, phospho-ERK (P-ERK) (right) of HMVEC-L exposed or not to 0.1, 0.3 or 0.5 Gy. The levels of Akt and ERK phosphorylation were
assessed after 5 or 60 min post-irradiation, respectively. (D) HMVEC-L were incubated in the presence or absence of a specific inhibitor of PI3K
(Ly294002-50 mM) (left) or MAPK (U0126-10 mM) (right) and then exposed or not to 0.1, 0.3 or 0.5 Gy. Cells cultured with vehicle alone were used as a
control.Cells were doublestained with Annexin-V andpropidiumiodide at36 h post-irradiation. Thepercentage of apoptotic cellswasassessed by flow
cytometry. The values (means 6 s.d.) are given as the percentage of viable cells and are derived from four independent experiments.
*P,0.03.
doi:10.1371/journal.pone.0011222.g002
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PLoS ONE | www.plosone.org 5 June 2010 | Volume 5 | Issue 6 | e11222Figure 3. Low-dose IR protects microvasculature from bevacizumab-induced cell death by inducing VEGFR-2 activation. (A) Cells
were cultured without serum for 12 h and incubated with vehicle/VEGF (20 ng/ml) or bevacizumab (0.25 mg/ml)/VEGF (20 ng/ml) mixtures. Then,
cells were exposed or not to 0.1, 0.3 or 0.5 Gy and the percentage of apoptotic cells was assessed by flow cytometry at 48 h post-irradiation. Data
(means 6 s.d.) represent the ratio between cell viability percentage of each experimental condition and control condition and are derived from four
independent experiments. (B) Representative blots from four independent experiments. Cells were exposed or not to 0.1 Gy. Western blot analysis of
Low-Dose IR Is Pro-Angiogenic
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damage of organs at risk. Our present data suggest that these low
doses of IR promote angiogenesis and consequently tumor burden
and metastasis. We found that doses of 0.8 Gy or lower do not
cause cell cycle arrest or apoptosis. Molecularly, they led to rapid
phosphorylation of several cellular proteins including Akt and
ERK, which play relevant roles in microvascular endothelial cell
function. Interestingly, our results suggest that there is not a
specific low IR-dose that is most effective in activating specific
cellular proteins and molecular response induced by low dose-IR,
since effects are dependent not only on the IR dose but also on the
molecular target. Doses of 0.1 and 0.3 Gy induce a similar
phosphorylation of AKT that is greater than the phosphorylation
induced by 0.5 Gy. On the other hand 0.1 Gy is more effective in
inducing phosphorylation of ERK, compared to 0.3 and 0.5 Gy
doses. Moreover, low-dose IR can protect endothelial cells against
apoptosis induced by inhibiting these signaling pathways. Thus,
low-dose IR might disrupt the balance between survival and
apoptosis by activating pro-survival signaling proteins, thereby
favoring angiogenesis. These findings do not contradict the
total- and phospho-VEGFR-2. (C) Cells were cultured without serum for 12 h and treated or not with VEGFR-2 tyrosine kinase inhibitor (TKI at 300 nM)
for 2 h and stimulated or not with VEGF (20 ng/ml) or bevacizumab (0.25 mg/ml)/VEGF (20 ng/ml) mixture. Then, cells were exposed or not to 0.1 Gy.
The percentage of apoptotic cells was assessed by flow cytometry at 48 h post-irradiation. Data (means 6 s.d.) represent the ratio between cell
viability percentage of each experimental condition and control condition and are derived from four independent experiments.
*P,0.03. (D)
Representative blots from four independent experiments. Western-blot analysis of total- and phospho-VEGFR-2 (P-VEGFR-2) of HMVEC-L cultured
without serum for 12 h and treated or not with VEGFR-2 tyrosine kinase inhibitor (TKI at 300 nM) for 2 h and stimulated with VEGF (20 ng/ml) or
bevacizumab (0.25 mg/ml)/VEGF (20 ng/ml) mixture. (B and D) The level of VEGFR-2 phosphorylation was assessed after 15 min post-irradiation.
doi:10.1371/journal.pone.0011222.g003
Figure 4. Low dose IR enhances hypoxia-induced VEGF expression. Cells were cultured with or without CoCl2 (150 mM) in normoxia to mimic
hypoxic conditions and immediately exposed or not to 0.3 Gy of IR. (A) 4 h (left graph) and 12 h (right graph) post-irradiation, VEGF mRNA was
quantified by qRT-PCR. Data (means 6 s.d.) represent the fold change in gene expression relative to the internal calibrator (2CoCl2) in triplicate
measurements and are representative of three independent experiments. (B) 72 h post-irradiation, VEGF protein was assessed by VEGF ELISA Kit. Data
(means 6 s.d.) indicate the VEGF concentration in quadruplicate measurements and are representative of three independent experiments.
*P,0.03.
doi:10.1371/journal.pone.0011222.g004
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PLoS ONE | www.plosone.org 7 June 2010 | Volume 5 | Issue 6 | e11222Figure 5. Low-dose IR accelerates angiogenic sprouting during zebrafish embryonic development and enhances angiogenesis
during fin regeneration. (A–C) Live zebrafish embryos were exposed or not to 0.5 Gy IR 3 d post-fertilization (dpf). Representative images of Sub-
Intestinal Vessels (SIV), from (A) a non-irradiated and irradiated zebrafish at 7 dpf; (B) an irradiated zebrafish at 5 (top), 6 (middle) and 7 dpf (bottom);
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cells contribute to antitumoral treatment, since these effects occur
only at high IR doses [21]. Rather, they suggest that at given doses
and at time points during radiotherapy, IR might enhance the
formation of new vessels, thereby favoring metastatic spreading.
We also demonstrated a protective effect of low-dose IR against
endothelial cell death induced by bevacizumab, an anti-VEGF
monoclonal antibody, currently used in the clinic as anti-
angiogenic drug in combination with chemotherapy [22]. VEGF
inhibition by bevacizumab can prevent binding to its receptors, in
particular VEGFR-2 which is the main pro-angiogenic VEGF
receptor on endothelial cells [22,23]. Consistently, we found that
low-dose IR activates VEGFR-2 and the protective effect of IR
against bevacizumab-mediated VEGF inhibition was completely
abrogated by treatment with a VEGFR-2 TKI. Therefore, we
propose that low-dose IR might prevent endothelial cells death
promoted by bevacizumab through a mechanism involving
VEGFR-2 phosphorylation. We observed that low-dose IR
enhanced endothelial cell migration by activating VEGFR-2.
While this result is partially consistent with previous reports
(C) an irradiated zebrafish at 7 dpf and a non-irradiated zebrafish at 17 dpf. Scale bars, 250 mm (A and C), 100 mm (B). (D) Fli1:EGFP adult zebrafish
caudal fins were amputated at mid-fin level, exposed or not to 0.5 Gy of IR and then allowed to recover. Representative images from vasculature of
two zebrafish fins (i and ii) before amputation ensure they had identical vasculature (top). Representative images from vasculature of two different fin
areas of the same zebrafish, 16 days post-amputation (dpa), with or without low-dose IR treatment (middle and bottom). Each image was quantified
for inter-ray vessel density. Data are shown as mean and error bars indicate maximum and minimum values. Images are representative of 10 zebrafish
in five independent experiments. Scale bars, 250 mm.
doi:10.1371/journal.pone.0011222.g005
Figure 6. Low-dose IR enhances angiogenesis in Matrigel plug assay. Angiogenesis was induced by injection of growth factor-depleted
Matrigel with FGF2. (A) Macroscopic evaluation of the Matrigel plugs explanted 5 d after injection in non-irradiated and 0.3 Gy preirradiated area.
Scale bars, 500 mm. (B) Angiogenesis was quantified by determining the angiogenic index. Inset shows the mean difference of angiogenic index
between paired mice. * P,0.025.
doi:10.1371/journal.pone.0011222.g006
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migration [8], it also suggests that low-dose IR might modulate
other molecules involved in endothelial cell migration since the
treatment with a VEGFR-2 TKI does not completely suppress IR-
induced migration.
Our data also showed that low-dose IR induces VEGF
transcription and consequent protein expression in endothelial
cells under hypoxia-mimicking conditions. CoCl2 induces the
expression of the transcription factor hypoxia-inducible factor 1
(HIF-1) a subunit, which leads to the increased transcription of
genes involved in the initiation and progression of angiogenesis
[9]. In normoxia, HIF1 activity is low and consequently the
endothelial cells express basal levels of VEGF [9]. We found that
these levels were not changed by low-dose IR. However, after
CoCl2 treatment and low-dose IR exposure, the expression of
VEGF is higher than in non-irradiated cells treated with CoCl2
alone. Although our data do not explain the mechanism by which
low-dose IR upregulates VEGF under hypoxic conditions, this
finding is of potential clinical relevance since hypoxic areas are
naturally present both within tumor and in its periphery [24]. The
exposure of hypoxic areas in the healthy tissues surrounding the
tumor to low doses of IR may further enhance VEGF expression
and favor tumor cell escape.
Taken together, our in vitro results suggest that low-dose IR
promote endothelial cell events, including the activation of
VEGFR, critical to the angiogenic process. Accordingly, we found
that low-dose IR increases vessel density in adult fli1:EGFP
zebrafish and mice and accelerates vessel formation by inducing
angiogenic sprouting in fli1:EGFP embryos. This pro-angiogenic
effect of low dose IR may be of clinical relevance, since low doses
of IR promoted tumor spreading of leukaemic cells and lung
metastasis formation of breast cancer in mice. According to our in
vitro results where we demonstrated an activation of VEGFR-2 by
low-dose IR, the VEGF receptor tyrosine kinase inhibitor PTK/
ZK, was administered before irradiation in order to avoid the
effect of low dose IR in inducing the phosphorylation of VEGFR
in mice irradiated with 0.3 Gy. It is described that the activation of
VEGFR leads to a rapid activation of different cellular proteins
and consequently to the de novo mRNA and protein expression of
mediators involved in the angiogenic response. This is strongly
supported by the data we obtained in an in vitro microarray study,
where several transcripts encoding for proteins required for
angiogenesis are induced upon low-dose IR delivery (data not
shown). However, since tumor cells also express VEGFR, PTK/
ZK would directly interfere with their viability thereby confound-
ing the results of the experiment. For that reason, the MOLT-4 or
4T1 cells were injected 24 h after PTK/ZK treatment, a time
point this inhibitor is no longer active in vivo. We observed that in
both mice models the experimental group treated with PTK/ZK
presented tumor spreading and lung metastasis formation similar
to the unirradiated experimental group, consistent with the
hypothesis that IR promoted tumor spreading of leukaemic cells
and lung metastasis through a mechanism involving the activation
of VEGFR. Two putative vascular beds might be involved in this
effect: the vascular beds that surrounds the primary tumor (which
provides an efficient exit route for tumor cells); and the vasculature
located in the metastatic organ (which will favor initial tumor cells
homing and supply oxygen and nutrients necessary for the
proliferation and survival of metastatic tumor cells).
In conclusion, our findings provide new insights into tumor
radiobiology, identifying the pro-angiogenic effects that low-dose
IR might have on the vasculature surrounding the tumoral mass,
and thus adding a clinically relevant element to the interpretation
of dosimetry in radiotherapy.
Materials and Methods
Ethics Statement
All animals experiments were carried out in accordance with
protocols approved by the Animal Care Committee of the IMM
(permit numbers AEC_004, AEC_005 and AEC_007).
Cell culture and reagents
Lung Human Microvascular Endothelial Cells (HMEC-L) were
purchased from Cambrex and cultured according to manufactur-
er’s instructions. Cells were used up to passage 6. T-cell leukemia-
derived MOLT-4 cells and 4T1 breast carcinoma cells (American
Type Culture Collection), both stably expressing luciferase, were
cultured in RPMI and 10% FBS. Ly294002 (50 mM), VEGF
(20 ng/ml) and CoCl2 (150 mM) were purchased from Sigma.
U0126 (10 mM) was purchased from New England Biolabs. VEGF
receptor-2 tyrosine kinase inhibitor (VEGFR-2 TKI) (70nM) was
purchased from Calbiochem. PTK787/ZK222584 (PTK/ZK)
(100 mg kg
21) was provided by Novartis Pharma AG, Basel,
Switzerland. Bevacizumab (0.25 mg/ml), 5-FU (5 mg/ml), gemci-
tabine (0.08 mM) and paclitaxel (3 nM) were provided by the
Oncology Service of Santa Maria Hospital, Lisbon, Portugal.
Irradiation
HMVEC-L cultures, anesthetized mice or zebrafish were
transferred to an acrylic phantom box in order to achieve a
certain thickness. A computed tomography (CT) scan (Somatom
Sensation, Siemens) was performed and a volumetric acquisition
was carried out; acquired images were reconstructed with axial
slices width of 1 mm, and cross sectional data was transferred to
the image processing system work station for contouring the
planning target volume (PTV). The radiotherapy plan was devised
on a dedicated 3D planning system (PLATO, Nucletron) using an
isocentric dose distribution of two opposite fields (0u, 180u)a t6
MV energy, normalized to a reference point. IR delivery was
performed at room temperature using a linear accelerator x-rays
photon beam (Varian Clinac 2100 CD) operating at a dose rate of
300 MU/min. A 0.6 cm
3 PTW farmer ionizing chamber,
connected to UNIDOS electrometers, was used to validate the
Figure 7. Low-dose IR promotes acceleration of tumor growth and metastasis in a VEGF receptor-dependent manner. (A) NOD-SCID
mice were irradiated or not with 0.3 Gy and 22 h later injected with MOLT-4 cells (B) NOD-SCID mice were pre-treated with PTK/ZK (100 mg/Kg) or
PTK/ZK vehicle, 2 h later irradiated or not with 0.3 Gy and after 22 h injected intravenously with MOLT-4 cells. (A and B) 14 d post-injection, the
tumor burden was quantified by bioimaging. n=3 mice per group. The values (means 6 s.d.) are representative of three independent experiments.
Dorsal images from representative mice are shown.
*P,0.02. (C) NOD-SCID IL-2R gamma
null mice were treated with PTK/ZK (100 mg/Kg) or PTK/ZK
vehicle, 2 h later irradiated or not with 0.3 Gy and after 22 h injected with 4T1 cells into the mammary fat pad. 20 d post-injection, the primary tumor
was removed and lung metastases were quantified by bioimaging. n=3 mice per group. The values (means 6 s.d.) are representative of three
independent experiments.
*P,0.05. Ventral images from representative mice were shown. (D) Representative images of CT cross section of lung area,
from one mouse per experimental condition, showing pulmonary nodules in both lobes of lungs (left). Schematic illustration (right) of the pulmonary
nodules (in red) located in both lobes (L) of the lungs. The gray area represents the heart (H). (E) Representative lung sections from one mouse per
experimental condition stained with H&E. Scale bars, 1 mm (top), 0.5 mm (bottom).
doi:10.1371/journal.pone.0011222.g007
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protocol. We obtained, in average, differences lower than 2%
between the experimental and the PLATO planning system dose
values.
Wound healing assay
HMVEC-L were plated to confluence and wounds created in
the monolayer by scraping the plate with a pipette tip. Monolayers
were irradiated or not and photographed immediately after
wounding and 9 h later.
Proliferation and cell cycle analysis
Cells were counted using a nucleocounter (ChemoMetec)
according to manufacturer’s instructions. Cell cycle assays were
performed as described [25] and analyzed using a FACS Calibur
(Beckton Dickinson) and ModFit LT 2.0 Software.
Apoptosis analysis
HMEC-L were plated at equal densities, after 12 h incubated in
the different experimental conditions and stained with Annexin V-
FITC (Boehringer Manheim) and propidium iodide (PI) (Inter-
chim). The percentage of apoptotic cells (Annexin V positive, PI
negative and positive) was determined by flow cytometry (FACS
Calibur, Beckton Dickinson) and Flowjo 6.4.7 Software. Results
are shown as the percentage of viable cells (Annexin V, PI
negative).
Immunofluorescence analysis
HMEC-L were cultured on gelatin-coated glass coverslips. The
cells were fixed, permeabilized, and incubated with antibody to c-
H2AX (from Upstate Biotechnology Inc.) followed by incubation
with Alexa Fluor 488 (Molecular Probes). The samples were
counterstained with DAPI and analyzed by fluorescence micros-
copy (Axioplan Microscope, Zeiss).
Flow cytometry analysis
The cells were fixed, permeabilized and stained with the
antibody to phospho-tyrosine (Santa Cruz Biotechnology) followed
by incubation with Alexa Fluor 488 or 594 (Molecular Probes). We
acquired cells using FACS Calibur (Beckton Dickinson) and
analyzed data using Flowjo 6.4.7 Software.
Western-blot analysis
Whole protein extracts were prepared as described [26]. Blots
were incubated with antibodies to phospho-tyrosine, phospho-
ERK (Tyr204), ERK, phospho Akt (Ser473), Akt (Santa Cruz
Biotechnology), VEGFR-2 (Calbiochem) or b-tubulin (Sigma).
Quantitative RT-PCR
For quantitative RT-PCR, total RNA was isolated using the
QiaShredder and RNeasy (Qiagen) system. For each sample, 1 mg
RNA was reverse transcribed into cDNA (Superscript II Kit,
Invitrogen). VEGF mRNA levels were measured by RT-PCR
(TAQMAN) on the ABI PrismH 7900HT Sequence Detection
System (Applied Biosystems) using specific primers and probes
(forward primer: 59-CCAGCACATAGGAGAGATGAGCTT-39,
reverse primer: 59-CGCCTCGGCTTGTCACA-39, probe:
6-FAM-59-ACAGCACAACAAATGTGAATGCAGACCAAA-
39-TAMRA). The housekeeping gene used to normalize the
samples in TAQMAN assay was the 18S (Human 18S rRNA-
206, Applied Biosystems). Real time PCR program consisted of
an initial denaturation step at 95uC for 10 min followed by 40
cycles at 95uC for 15 s and at 60uCf o r1m i n .T h er e l a t i v e
quantification of VEGF mRNA in HMEC-L was performed
according to the comparative method (2 2DDCt; Applied
Biosystems User Bulletin no. 2P/N 4303859), with 2CoCl2
condition as internal calibrator. The formula used is 2 2DDCt =2
2[DCt(sample)2DCt(calibrator)], where DCt(sample)=Ct(sam-
ple)2Ct(reference gene). For the internal calibrator, DDCt=0 and
2 0=1. For the remaining samples, the value of 2 2DDCt indicates
the fold change in gene expression relative to the calibrator. DCt
value for each sample is the average of triplicates.
ELISA assay
Conditioned medium from the different experimental condi-
tions was stored at 280uC and VEGF concentrations were
measured following manufacturer’s instructions using the human
VEGF-ELISA kit (Calbiochem).
Zebrafish
The transgenic zebrafish fli1:EGFP were obtained from the
Zebrafish International Resource Center and maintained under
standard conditions [27] with institutional animal care. Before
irradiation or imaging, adults and embryos zebrafish were
anesthetized using 0.61 mM and 0.31 mM of tricaine, respective-
ly. Caudal fins were acquired on a Zeiss LSM 5 Live microscope
using a 106/0.30 objective and a solid state 488 nm laser in
conjunction with a LP 505 nm filter. Zebrafish embryos images
were acquired on a Zeiss LSM 510 META using a 206/0.80
objective and the 488 nm laser line of an Ar laser in conjunction
with a LP 505 nm filter. The vessel density was calculated with
Image J (NIH) using threshold segmentation and histogram
analysis to measure blood vessel areas per total area of selected
regions of interest (inter-ray regions).
Mice and mouse procedures
Athymic Swiss nu/nu, NOD-SCID and NOD-SCID IL-2R
gamma
null mice were purchased from the Harlan Laboratories
(Madison, WI, USA), the pathogen-free facility of the Instituto de
Medicina Molecular (IMM) and the Jackson Laboratory (Bar
Harbor, Maine, USA), respectively. Matrigel plug angiogenesis
assay was adapted from the original method [12]. Briefly, 24 h
after 0.3 Gy local radiation of 8 week-old Athymic Swiss nu/nu
female mice (lower-right back side), two Matrigel plugs (400 ml/
plug) supplemented with FGF-2 (500 ng/ml, PeproTech EC Ltd)
and Heparin (3 U/ml, Sigma) were implanted in the irradiated
dorsal region of the mice or in the contralateral non-irradiated side
(control plug) of same mouse. Five days after Matrigel implanta-
tion, the plugs were removed and photographed using 0.566
magnification. Angiogenesis was reported as the angiogenic index
(mean number of red pixels per the total number of pixels in the
area of interest) using the Image J (NIH). 6-week-old NOD-SCID
mice were injected intravenously (i.v.) with 20610
6 MOLT-4 cells.
6 week-old NOD-SCID IL-2R gamma
null female mice were
injected with 5610
4 4T1 cells suspended in 50% PBS/50%
Matrigel (from BD Biosciences) into the 4
th mammary fat pad.
PTK/ZK or its vehicle (polyethylene glycol-300 from Sigma) was
administered by intragastric gavage. For imaging studies, mice
were anesthetized and injected with D-luciferin at 150 mg kg
21
(Xenogen) intraperitoneally (i.p). We imaged photonic emission
with the In Vivo Imaging System (IVIS, Xenogen) with a collection
time of 180 s for MOLT-4 experiments or 10 s for 4T1
experiment. We quantified tumor bioluminescence by integrating
the photonic flux (photons per second) through a region encircling
each tumor, as determined by the LIVING IMAGES Software
package (Xenogen). We evaluated lung metastasis by Computed
Tomography (CT) scan. Acquired images were reconstructed with
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were dissected, immersion-fixed overnight, at room temperature,
in 4% paraformaldehyde and then embedded in paraffin. Paraffin-
embedded sections with 3 mm thickness were counterstained with
hematoxylin and eosin (H&E) using traditional methods.
Statistical analysis
Numeric data were analyzed for statistical significance using
Mann-Whitney test for comparison of means with GraphPad
Prism 5 Software. Two-tailed unpaired and paired Student’s t-test
was also used for tumor and Matrigel plug assay experiments,
respectively. P,0.05 was considered significant.
Supporting Information
Figure S1 Low doses of IR induce phosphorylation of H2AX.
Cells were exposed or not to 0.3, 0.5, 1.0 and 2.0 Gy and *-H2AX
foci, marking DNA damage, were visualized, by immunofluores-
cence microscopy, after 30 min and 12 h post-irradiation.
*-H2AX foci are shown in green and nuclei are stained with
DAPI (in blue). Magnification, 4006.
Found at: doi:10.1371/journal.pone.0011222.s001 (1.07 MB TIF)
Figure S2 Low doses of IR do not protect the microvasculature
from 5-FU-, gemcitabine- or paclitaxel-induced cell death.
HMVEC-L were cultured for 12 h and treated or not with (A)
5-FU (5 * g/ml); (B) gemcitabine (0.08 * M); (C) paclitaxel (3 nM)
and then exposed or not to 0.1, 0.3 or 0.5 Gy. Non-irradiated cells
cultured with vehicle alone were used as a control. Cells were
double stained with Annexin-V and propidium iodide at 48 h
post-irradiation. The percentage of apoptotic cells was assessed by
flow cytometry. Data (means 6 s.d.) represent the ratio between
the cell viability percentage of each experimental condition and
the control condition and are derived from four independent
experiments.
Found at: doi:10.1371/journal.pone.0011222.s002 (0.38 MB TIF)
Figure S3 Low-dose IR promotes endothelial cell migration by
activating VEGFR-2. Confluent monolayers of HMVEC-L were
treated or not with VEGFR-2 tyrosine kinase inhibitor (TKI at
300 nM) for 2 h, subjected to in vitro wound healing and next
exposed or not to 0.5 Gy. The quantification of the wound area (in
mm2) was assessed 9h after wounding. Data (means 6 s.d.)
indicate the percentage of wound recovery in quadruplicate
measurements and are representative of three independent
experiments. *P,0.05.
Found at: doi:10.1371/journal.pone.0011222.s003 (0.13 MB TIF)
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